Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow FATE THERAPEUTICS INC

Get SEC filing alerts via email and in your feed for FATE THERAPEUTICS INC

FATE

FATE THERAPEUTICS INC

About FATE THERAPEUTICS INC

Fate Therapeutics is a biopharmaceutical company developing off-the-shelf cellular immunotherapies using proprietary induced pluripotent stem cell (iPSC) technology. Its focus includes engineered T-cell and natural killer (NK) cell products for autoimmune diseases and solid tumors. The company leverages innovative synthetic controls, gene editing, and scalable manufacturing to create targeted, durable, and accessible cell therapies aimed at addressing unmet medical needs across cancer and autoimmune indications.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from FATE THERAPEUTICS INC

1
1
FATE THERAPEUTICS INC Fate Therapeutics Reports $31.2 Million Net Loss in Q1 2026

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
FATE THERAPEUTICS INC Fate Therapeutics Reports 2025 Financial Results and Strategic Developments

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
FATE THERAPEUTICS INC Fate Therapeutics Reports Decrease in Collaboration Revenue and Operating Losses for Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
FATE THERAPEUTICS INC Fate Therapeutics Reports Decrease in Collaboration Revenue and Net Loss for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
FATE THERAPEUTICS INC Fate Therapeutics Reports Q1 2025 Financial Results with Decreased Revenue and Improved Loss Per Share

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
FATE THERAPEUTICS INC Fate Therapeutics Reports $186.2 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
FATE THERAPEUTICS INC Fate Therapeutics Reports Q3 2024 Financial Results, Collaboration Revenue Decreases Due to Janssen Biotech Termination

Via official filing (AI summary) | over 1 year ago | 0 comments